Medicinal products and active pharmaceutical ingredients (APIs) subject to safety, efficacy, and quality regulations, including the assessment of carcinogenic, mutagenic, or reprotoxic (CMR) properties and impurities.
Foresight tracks Pharmaceuticals developments and surfaces the alerts most likely to matter before they turn into missed deadlines, recalls, or escalation work.
Not ready for a trial? Take the 3-minute readiness assessment
Current activity
83% above the prior 8-week baseline
3-month trend
Latest alerts below
Last updated
25 May 2026, 15:47
Source-backed regulatory and guidance signals tracked by Foresight, with the newest developments first.
Netherlands IGJ Grants Temporary Exemption for Gonasi 5000 IU Owing to Medicine Shortage
The Dutch Health and Youth Inspectorate has granted a temporary exemption until 21 August 2026 allowing import and dispensing of Gonasi 5000 IU fertility medicines without a Dutch marketing authorisation to address a national shortage. This mitigates short-term supply and treatment risks for infertility care while imposing strict indication limits and record-keeping obligations on manufacturers, wholesalers and pharmacies sourcing equivalent products from other authorised markets.
NetherlandsUS FDA Schedules VRBPAC Meeting and Opens Docket for MFLUSIVA mRNA Influenza Vaccine
The US FDA has scheduled a 18 June 2026 meeting of its Vaccines and Related Biological Products Advisory Committee and opened a public comment docket to review the safety and effectiveness of Moderna’s MFLUSIVA mRNA influenza vaccine for adults aged 50 and over. This marks an advanced stage in the vaccine’s US licensure process and gives manufacturers, clinicians, and other stakeholders a short window to contribute evidence and testimony that may influence FDA’s benefit–risk assessment and future market authorisation.
United StatesNetherlands IGJ Extends Shortage Exemption for Fenobarbital Teva 50 mg (RVG 52101) Until 6 July 2026
IGJ has extended a temporary exemption so Dutch manufacturers, wholesalers and pharmacists can continue importing and dispensing alternative registered phenobarbital 50 mg tablets to cover an ongoing shortage of Fenobarbital Teva 50 mg (RVG 52101) through early July 2026. This maintains epilepsy treatment continuity but requires strict adherence to indication, sourcing and record-keeping conditions while companies prepare to switch back to normally authorised supply once stock recovers.
NetherlandsEU EESC Adopts Opinion on Life Science Strategy and Rare-Disease Research Infrastructures
In February 2026 the European Economic and Social Committee adopted an exploratory opinion calling for an integrated EU life-science strategy that prioritises rare-disease research, genomic data infrastructures and faster market access for advanced therapies. While non-binding, this signals political momentum for revising frameworks such as the European Health Data Space, the AI Act and key food-chain regulations, with potential future impacts on approval pathways, data-use rules and innovation incentives for pharma, biotech and related supply chains.
European UnionUS FDA Seeks OMB Review of Adverse Event Reporting Information Collection for Approved New Animal Drugs
FDA has sent its adverse event reporting information collection for approved new animal drugs (OMB Control No. 0910-0284) to OMB for final review under the Paperwork Reduction Act, with public comments due by 22 June 2026. This extends existing postmarketing safety reporting and recordkeeping requirements for animal drug sponsors and feed manufacturers while confirming significantly higher expected reporting and recordkeeping burdens as product use and associated case volumes grow.
United StatesEU Council Starts Procedure To Consult EESC and CoR on European Biotech Act Proposal
In May 2026, the Council’s General Secretariat launched a short silence procedure to approve consulting the EU’s advisory committees on the proposed European Biotech Act, which would create an EU framework for biotechnology and biomanufacturing in health and amend key food and medicines regulations. This marks the file’s move deeper into the Council phase of co-legislation, signalling that biotech, pharma, veterinary and food operators should track ensuing opinions and negotiations that could reshape product authorisation pathways and regulatory oversight.
European UnionChina MEE Seeks Comments on Seven Draft National Water Pollutant Emission Standards for Petrochemical and Pharmaceutical Industries
China's Ministry of Ecology and Environment is consulting until 20 June 2026 on seven draft national water pollutant emission standards for the petrochemical industry and six pharmaceutical manufacturing segments. These standards are expected to define and harmonise national wastewater discharge requirements across key chemical and pharma sectors in China, with implications for permitting, monitoring and investment in treatment and compliance.
ChinaAustralia TGA Clarifies Import and Supply Rules for Cosmetic Injectables
Australia’s Therapeutic Goods Administration has issued a factsheet reminding health practitioners that only sponsors or their agents may import cosmetic injectable medicines and devices for commercial supply, and that parallel-imported or otherwise unapproved products are unlawful. The guidance signals heightened enforcement focus on cosmetic injector supply chains, so clinics and wholesalers should review sourcing, ARTG status and use of formal access pathways to avoid product loss, penalties and referral to professional regulators.
AustraliaAustralia TGA Issues Product Correction for Flixotide and Pavtide Accuhaler Batches
Australia’s medicines regulator has issued a product correction for defined batches of GSK’s Flixotide and Pavtide Accuhaler asthma inhalers after finding some devices may stop automatically reloading doses, risking short-term loss of symptom control. Marketing authorisation holders, distributors and healthcare providers should identify any affected stock, reinforce the TGA’s handling and communication guidance with prescribers and patients, and review post-market surveillance for similar device-performance issues across inhaler portfolios.
AustraliaNew Hampshire Legislature Enrols HB1192 To Exempt Certain Household Pharmaceutical Wastes From Hazardous Waste Definition
The New Hampshire legislature has passed HB1192, enrolling a bill that would exclude certain household pharmaceutical wastes collected under RSA 318-E from the state’s statutory definition of hazardous waste. Once enacted, this exemption will ease regulatory burdens on household pharmaceutical take-back programmes and clarify waste classification obligations for municipalities, pharmacies, and hazardous-waste contractors.
United StatesGerman Bundestag Holds First Reading of Bill to Strengthen Medical Registers
In May 2026 the German Bundestag held the first reading of a federal bill to create a Medical Registers Act and amend social security and implant register law, establishing a unified framework and new governance for more than 350 medical registries and their health data use. If adopted, this regime will formalise qualification and interoperability requirements, expand permitted reuse and linkage of registry data, and reshape compliance strategies for medical device and pharmaceutical firms that run or rely on clinical registries and real-world evidence.
GermanyGerman Bundestag Adopts Pharmacy Reform Law (Apothekenversorgung-Weiterentwicklungsgesetz)
In May 2026 the German Bundestag adopted the Apothekenversorgung-Weiterentwicklungsgesetz, a far-reaching pharmacy reform that strengthens community pharmacies, expands their clinical and preventive tasks, and introduces tightly framed pharmacist prescribing powers for certain chronic and acute conditions. Once promulgated, the law will materially change how medicines, vaccinations and diagnostics are delivered through German pharmacies, while piloting PTA-led operations in rural areas and preparing a new remuneration framework that pharmacy operators and healthcare suppliers need to factor into medium-term planning.
GermanyUS Select Committee Chair Urges Treasury To Treat Biotechnology As Prohibited Outbound Investment Under COINS Act
In May 2026, the chair of the US House Select Committee on China urged the Treasury Secretary to designate biotechnology as a prohibited sector for outbound US investment under the new COINS Act, citing rapid growth in US and multinational licensing and co-development deals with Chinese biotech firms. If Treasury follows this guidance, biotechnology and pharmaceutical companies involved in cross-border licensing, co-development or manufacturing partnerships with Chinese counterparts could face significantly tighter outbound investment screening and constraints on capital and know-how flows.
United StatesUS FDA Approves ERVEBO Labelling Supplement (20 April 2026)
In April 2026, the US FDA approved a labelling supplement for Merck’s ERVEBO Ebola vaccine, adding Phase 2 safety and immunogenicity data for HIV-infected adults and adolescents. Regulatory and commercial teams must rapidly finalise and submit updated electronic labelling and ensure promotional materials align to avoid compliance risk around ERVEBO’s use in these populations.
United StatesUS FDA Approves BLA Supplement for VIMKUNYA Manufacturing Process and Labelling
US FDA has approved a biologics license supplement for Bavarian Nordic’s VIMKUNYA chikungunya vaccine, confirming optimised CHIKV VLP manufacturing processes and associated labelling changes in the US market. This creates near-term obligations for SPL labelling submissions and promotional materials oversight, so regulatory, quality and commercial teams should coordinate to ensure timely, compliant implementation.
United StatesUS FDA Approves HEMGENIX Labelling Supplement (29 April 2026)
On 29 April 2026, FDA’s Center for Biologics Evaluation and Research approved a Biologics License Application supplement for HEMGENIX to update the US Prescribing Information based on new efficacy and safety data. CSL Behring must implement the revised labelling and submit final Structured Product Labelling content within 14 days, ensuring all promotional materials align with the updated information and regulatory requirements.
United StatesOregon Health Authority Proposes 12-Month Medicaid Dispensing for Selected Hormone Therapies
In May 2026 the Oregon Health Authority proposed amending Medicaid rule OAR 410-121-0146 to allow 12-month dispensing of selected hormone therapies for Oregon Health Plan fee-for-service members, with a hearing on 16 June and comments due 21 June 2026. If adopted, pharmacies and prescribers serving Oregon Medicaid would be able to dispense once-yearly supplies of specified hormone drugs (subject to storage and controlled-substance limits), improving treatment continuity but requiring updates to prescribing practices, inventory management and benefit administration.
United StatesItaly Official Gazette Publishes Minor Variation To Flurbiprofen Teva Marketing Authorisation
Italy’s Official Gazette has published a minor variation to the marketing authorisation for Flurbiprofen Teva, updating SmPC, leaflet and labelling wording on NSAID-related female fertility risks with clear implementation deadlines for the MA holder and pharmacists. MA holders and pharmacists must now update and distribute the revised patient information within the specified timelines, reinforcing pharmacovigilance expectations for women of childbearing potential in Italian NSAID prescribing and dispensing.
ItalyItaly AIFA Revokes Marketing Authorisation for Rivaroxaban Polpharma
In May 2026 the Italian Medicines Agency revoked, at the holder’s request, the marketing authorisation in Italy for the rivaroxaban-based medicinal product Rivaroxaban Polpharma across all listed strengths and pack sizes. Existing stocks may only be sold until 17 November 2026, so companies relying on this presentation should secure alternative rivaroxaban supply and adjust distribution plans.
ItalyGermany’s Environment Agency Publishes Feasibility Study On Environmental Index For Pharmaceuticals
Germany’s Environment Agency has released a major feasibility study proposing an environmental information and classification system for pharmaceuticals to curb medicine residues in water over the coming years. If implemented, this “Arzneimittelindex Umwelt” could hard‑wire environmental performance of active ingredients into prescribing, reimbursement and procurement decisions, reshaping how pharmaceutical portfolios and treatment guidelines are managed.
GermanyThese are just a few of the most recent Pharmaceuticals alerts. Foresight tracks every jurisdiction, every day — and surfaces only what affects your portfolio, with full citations and evidence.
Start free trialTopic context
Definition
Medicinal products and active pharmaceutical ingredients (APIs) subject to safety, efficacy, and quality regulations, including the assessment of carcinogenic, mutagenic, or reprotoxic (CMR) properties and impurities.
Industry relevance
Pharmaceuticals developments can change product scope, supplier expectations, market access, reporting duties, and risk ownership. Foresight tracks the signals early so teams can respond before obligations become urgent.
Foresight tracking
Foresight monitors official sources, extracts structured regulatory intelligence, and maps alerts to a customer's products, substances, markets, and priorities so teams see the relevant signal with source evidence for review.
Everything you need to know about Foresight's regulatory intelligence platform
Still have questions? Get in touch with our team
Subscribe to Foresight Weekly for expert-picked regulatory developments across chemicals, sustainability, product safety, ESG, and HSE.
Free forever. Unsubscribe anytime.
Read by professionals at
